A theme aimed at advancing next-generation strategic products into the clinical stage and contributing to profits in the pharmaceutical business through obtaining approvals for, launching sales of, and filing applications for products including anti-HIV drugs. Ultimately, the relevant business was transferred to Shionogi & Co., Ltd. and excluded from continuing operations.